Concepedia

Author

N. Androulakis

University Hospital of Heraklion

Also Known As

N Androulakis, N. Androulakis, Nicos Androulakis

36

Publications

926

Citations

15

H-Index

19

Concepts

All Affiliations

University Hospital of HeraklionUniversity of CreteSotiria General HospitalKAT General Hospital of AtticaSismanoglio General Hospital
NA

About

N. Androulakis is an author at University Hospital of Heraklion specializing in medicine, cancer therapeutics, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

6

6

221

2

Pathology

3

3

95

3

Pharmacology

2

2

104

4

Health Sciences

1

1

41

5

Surgical Oncology

1

1

52

N. Androulakis

×

15

Publications

887

Citations

15

H-Index

YearCitations

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)

John Souglakos, N. Androulakis, K. Syrigos,

British Journal of Cancer

2006

399

Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy

John Souglakos, A. Kalykaki, L. Vamvakas,

Annals of Oncology

2006

63

Combination of Irinotecan (CPT-11) plus 5-Fluorouracil and Leucovorin (FOLFIRI Regimen) as First Line Treatment for Elderly Patients with Metastatic Colorectal Cancer: A Phase II Trial

John Souglakos, Athanasios Pallis, Stylianos Kakolyris,

Oncology

2005

62

A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial

Zenia Saridaki, N. Androulakis, N. Vardakis,

British Journal of Cancer

2012

56

First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study

Pavlos Papakostas, Ch. Kouroussis, N. Androulakis,

European Journal of Cancer

2001

52

Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study

Vassilis Georgoulias, Athina Agelidou, K. Syrigos,

British Journal of Cancer

2005

45

First-line treatment of advanced nonsmall cell lung carcinoma with docetaxel and vinorelbine

C. Kourousis, N. Androulakis, S. Kakolyris,

Cancer

1998

41

ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program

Athanasios Pallis, D. Mavroudis, N. Androulakis,

Lung Cancer

2003

33

Front-Line Chemotherapy with Docetaxel and Gemcitabine Administered Every Two Weeks in Patients with Metastatic Breast Cancer: A Multicenter Phase II Study

D. Mavroudis, Nikolaos Malamos, Aris Polyzos,

Oncology

2004

27

Salvage Treatment of Metastatic Breast Cancer with Docetaxel and Carboplatin

D. Mavroudis, A. Alexopoulos, Nikolaos Malamos,

Oncology

2003

20

Page 1